Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
Details for Australian Patent Application No. 2007306384 (hide)
International Classifications
Event Publications
4 June 2009 PCT application entered the National Phase
PCT publication WO2008/043777 Priority application(s): WO2008/043777
29 October 2009 Amendment Made
The nature of the amendment is: Add the names of co-inventors Mezazigh Hami, Assia and Supiot, Stephane
16 February 2012 Amendment Made
The nature of the amendment is: Amend the name of the inventor to read Supiot, Stephane; Chatal, Jean-Francois; Birkle, Stephane; Aubry, Jacques; Mussini, Jean-Marie and Barbet, Jacques 2007356192 LG Electronics, Inc. The nature of the amendment is as shown in the statement(s) filed 09 Aug 2011 2008
12 April 2012 Application Accepted
Published as AU-B-2007306384
28 June 2012 Application for Amendment
The nature of the amendment is as shown in the statement(s) filed 08 Jun 2012 . Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000 2008
25 October 2012 Amendment Made
The nature of the amendment is as shown in the statement(s) filed 08 Jun 2012 2008
1 November 2012 Standard Patent Sealed
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2007306399-Vinylogous acids derivatives as chymase inhibitors
2007306382-Substituted pyrazinone derivatives for use as a medicine
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser